PlainPharmaWatch Guide
How Much Do Pharma Companies Spend on Doctors?
A data-driven breakdown of pharmaceutical spending on physicians, total amounts, payment categories, year-over-year trends, and which companies dominate the rankings.
According to CMS Open Payments, pharmaceutical and medical device companies reported $13.9B in payments to physicians and teaching hospitals in Program Year 2024 across 1,925 reporting companies. Novartis Pharmaceuticals Corporation reported the largest single-company total in this dataset. Company totals reflect disclosed dollar volume, not conduct.
Key Takeaway
In Program Year 2024, pharmaceutical and medical device companies reported $13.9B in payments to physicians and teaching hospitals. The category table below distinguishes the General Payments records this site can break out from amounts CMS reports through other tracks. Company totals show disclosed dollar volume only, not company conduct.
The biggest pharma payers
Top 10 companies by total reported payments to physicians and teaching hospitals (live from the CMS Open Payments database)
The $13.9B Total
CMS Open Payments publishes payment disclosures from applicable manufacturers and group purchasing organizations. In Program Year 2024, the published records used by this site total $13.9B across 1,925 company records.
The total combines different CMS reporting tracks. It does not measure company revenue, marketing budgets, clinical value, or the appropriateness of any relationship. Browse the reporting companies to see the payment breakdown available for each record.
Spending by Payment Category
The $13.9B is not distributed evenly across payment types. CMS's own General Payments categories account for 24.6% of the total; the remainder is Research and other payments, which CMS reports through a separate track that this portal does not break out by category:
| Payment Category | Share of Total |
|---|---|
| Research & other (reported separately by CMS, not category-broken-out here) | 75.4% |
| Royalty or License | 6.2% |
| Compensation for Services Other Than Consulting | 5.1% |
| Consulting Fee | 4.1% |
| Food and Beverage | 3.0% |
| Acquisitions | 1.9% |
| Travel and Lodging | 1.5% |
CMS reports Research payments through a separate track. This site's category table does not divide that track into payment types, so it keeps the remainder separate rather than guessing at its composition. Explore the General Payments categories.
Top Spending Companies
The chart ranks the current dataset by reported total. A high total can reflect many different payment categories and recipient relationships. The ranking alone does not establish why a company appears where it does.
PlainPharmaWatch includes a profile for each company record. You can sort by total payments, transaction count, recipient count, or state. Browse company profiles for the available payment-type and recipient breakdowns.
Year-Over-Year Trends
This site retains a like-for-like comparison only where the same CMS manufacturer or GPO identifier appears in both program years. That is narrower than a full market trend, but it avoids treating a renamed, merged, or newly reported company as a change in the same entity.
Matched companies' General Payments by program year
1,838 companies with the same CMS identifier in each retained year
The chart is a trend for this matched set only. It does not describe the whole industry, and it does not say why the reported total changed. Read the release comparison for the underlying identifier-matched rows.
Geographic Distribution
The current ranking places California, Florida, Pennsylvania, and Massachusetts among the highest totals in the dataset. These are absolute reported dollars, not population-adjusted rates or a measure of care quality, prescribing, or company conduct.
Explore the state-level data for each state's reported total, recipient count, and payment breakdown.
What the total includes
The CMS total combines categories that are not interchangeable. This table keeps the site's directly broken-out General Payments separate from the remainder CMS reports through other tracks.
| CMS reporting scope | Reported amount |
|---|---|
| All records used by PlainPharmaWatch (PY2024) | $13.9B |
| Research & other, reported separately by CMS | $10.5B |
| General Payments with the available category breakdown | $3.4B |
These amounts should not be compared with a company's revenue, advertising expenditure, or research budget. They are disclosure totals under a particular federal reporting program.
What Transparency Reveals
Open Payments makes reported financial relationships publicly searchable. It can show the payment amount, payer, recipient, date, and category supplied in the CMS record.
It cannot show whether a relationship was appropriate, how a payment affected care, or whether a company's total reflects clinical value or misconduct. A reported payment is a disclosure, not a verdict.
Use PlainPharmaWatch to explore the data behind the numbers. Search companies, browse states, or view top recipients to see how $13.9B breaks down in detail.
Frequently Asked Questions
How much do pharmaceutical companies spend on doctor payments each year?
In Program Year 2024, pharmaceutical and medical device companies reported $13.9B in payments to physicians and teaching hospitals, covering 1,925 companies. PlainPharmaWatch shows the CMS-published total and separates its General Payments category table from amounts CMS reports through other tracks.
What is the largest category of pharma spending on doctors?
This site can show the individual General Payments categories in its database. CMS reports Research payments through a separate track, so PlainPharmaWatch does not label one research subcategory as the largest without a matching CMS category table.
Which companies spend the most on doctor payments?
In the current CMS dataset, Novartis Pharmaceuticals Corporation, Pfizer Inc., ModernaTX, Inc., Eli Lilly and Company, and Abbvie Inc. rank among the highest reported total spenders. The ranking is by disclosed dollar volume, not company size, product quality, clinical value, or conduct.
How do pharma payment levels compare to drug advertising spending?
Open Payments is not a total marketing-spend dataset. It records reportable transfers of value under the federal program. It should not be used to compare company advertising budgets or to estimate the return on any kind of marketing.
Have pharma payments to doctors increased or decreased over time?
This site currently keeps an identity-matched PY2022-to-PY2024 comparison for 1,838 companies. That matched-set trend is useful for comparing the same CMS manufacturer or GPO identifiers, but it is not a full market history.
Are smaller pharma companies also required to report payments?
CMS sets program eligibility and reporting thresholds. This guide does not determine whether a particular company was required to report. In PY2024, the published data used here contains 1,925 distinct company records.
Sources
This content is for informational purposes only and does not constitute medical or legal advice. Reported payments do not imply wrongdoing or inappropriate conduct. The figures describe the CMS records and their stated reporting scope; they do not establish the quality or appropriateness of care.